Get the Stockscreener App
0.2751
7.54%
0.0193
After Hours:
.28
0.0049
+1.78%
Sangamo Therapeutics Inc stock is traded at $0.2751, with a volume of 6.77M.
It is up +7.54% in the last 24 hours and down -27.26% over the past month.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A.
See More
Previous Close:
$0.2558
Open:
$0.26
24h Volume:
6.77M
Relative Volume:
1.02
Market Cap:
$113.97M
Revenue:
$39.55M
Net Income/Loss:
$-122.93M
P/E Ratio:
-0.622
EPS:
-0.4423
Net Cash Flow:
$-97.31M
1W Performance:
+8.01%
1M Performance:
-27.26%
6M Performance:
-60.13%
1Y Performance:
-62.73%
1-Day Range:
$0.248
$0.2899
1-Week Range:
$0.246
$0.2899
52-Week Range:
$0.205
$0.84
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
(510) 970-6000
Address
501 CANAL BLVD., RICHMOND, CA
Compare SGMO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.2751 | 105.97M | 39.55M | -122.93M | -97.31M | -0.4423 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-07-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-13-24 | Upgrade | Truist | Hold → Buy |
| Dec-10-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-21 | Resumed | Guggenheim | Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Dec-16-20 | Resumed | H.C. Wainwright | Buy |
| Sep-08-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | SunTrust | Buy |
| Aug-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Jun-20-18 | Initiated | BofA/Merrill | Buy |
| Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Dec-04-15 | Initiated | Wells Fargo | Outperform |
| Oct-23-15 | Resumed | Jefferies | Buy |
| May-03-13 | Initiated | BioLogic Equity Research | Sell |
| Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
| Jul-29-10 | Reiterated | Wedbush | Outperform |
| Oct-19-09 | Initiated | Brean Murray | Sell |
| Oct-07-09 | Reiterated | Leerink Swann | Outperform |
| Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks - MSN
SGMO News | SANGAMO THERAPEUTICS INC (NASDAQ:SGMO) - ChartMill
Fabry Disease Market Set for Robust Growth by 2034, Driven by Gene Therapy Breakthroughs and Expanding Pipeline from Sangamo, Sanofi, Amicus & Emerging Innovators | DelveInsight - Barchart.com
HC Wainwright Has Negative Forecast for SGMO FY2026 Earnings - MarketBeat
Analyst Calls: Will Sangamo Therapeutics Inc benefit from geopolitical trendsPortfolio Risk Summary & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
SGMO SEC FilingsSangamo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Sangamo (NASDAQ: SGMO) awards 225,000 stock options to accounting chief - Stock Titan
Sangamo (SGMO) CEO Sandy Macrae receives 2.5M stock option grant at $0.2601 - Stock Titan
Sangamo (NASDAQ: SGMO) CLO awarded 800,000 options at $0.2601 - Stock Titan
Equities Analysts Issue Forecasts for SGMO FY2028 Earnings - MarketBeat
Sangamo Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SGMO) 2026-04-02 - Seeking Alpha
Sangamo Therapeutics Nears Key Milestone with Accelerated FDA Pathway for Fabry Disease Therapy - aktiencheck.de
Sangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth Uncertainty - TipRanks
RBC Capital Maintains Sangamo Therapeutics(SGMO.US) With Hold Rating, Maintains Target Price $2 - Moomoo
Sangamo Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Sangamo: Q4 Earnings Snapshot - theheraldreview.com
Sangamo Reports Pipeline Progress And Wider FY25 Loss, Stock Down 17% Overnight - RTTNews
Sangamo Therapeutics (SGMO) Q4 Loss Highlights Deep TTM Deficit Challenging Bullish Profitability Hopes - Sahm
Sangamo Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Sangamo Therapeutics Inc (SGMO) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus
Sangamo Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Sangamo’s Q4 2025 earnings miss, stock fluctuates By Investing.com - Investing.com Australia
Sangamo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
SGMO Faces Uncertainty Without Additional Funding - GuruFocus
Sangamo Therapeutics | 8-K: SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS - moomoo.com
Sangamo (SGMO) Reports Robust Revenue Growth and Pipeline Progre - GuruFocus
Sangamo Therapeutics (NASDAQ:SGMO) Releases Quarterly Earnings Results, Misses Expectations By $0.12 EPS - MarketBeat
Earnings call transcript: Sangamo’s Q4 2025 earnings miss, stock fluctuates - Investing.com
Sangamo Therapeutics Q4 Loss Is Unchanged, Revenue Climbs - Moomoo
Sangamo Therapeutics earnings missed by $0.10, revenue fell short of estimates - Investing.com Canada
Q4 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
BRIEF-Sangamo Therapeutics Q4 EPS USD -0.11 - TradingView
Sangamo Therapeutics, Inc. Reports Unaudited consolidated Impairment Charges for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnin - Benzinga
Sangamo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Sangamo Therapeutics, Inc. Trade Ideas — LSX:936386 - tradingview.com
Sangamo Therapeutics Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Gains Report: Is Sangamo Therapeutics Inc a strong growth stockEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
If You Invested $1,000 in Sangamo Therapeutics Inc (SGMO) - Stock Titan
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call - The Manila Times
Sangamo will post 2025 results after the close on March 30 - Stock Titan
Sangamo Therapeutics (SGMO) NASDAQ US 18 Mar 2026: Market closed, earnings tonight - Meyka
EPS Watch: Does Sangamo Therapeutics Inc have consistent dividend growth2026 PostEarnings & Real-Time Buy Signal Notifications - baoquankhu1.vn
Sangamo seeks accelerated US approval of gene therapy for Fabry - Fabry Disease News
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Sangamo Biosciences (SGMO) and Protalix (PLX) - The Globe and Mail
Sangamo Therapeutics (SGMO) shares stabilize amid recent key pipeline update - MSN
Fabry Disease Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart
Sangamo (SGMO) Advances FDA Submission for Gene Therapy Approval - GuruFocus
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease - The Manila Times
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):